Poll Shows Readers Most Excited for PersevERA BC Trial Data at ASCO 2026
As the 2026 ASCO Annual Meeting draws near, a recent poll asked oncology readers which breast-cancer abstract they are most looking forward to.
Respondents could choose among several late-breaking abstracts, including PFS2 data from the ASCENT-04 trial (LBA1000), PFS2 data from the SERENA-6 trial (LBA1007), the phase 3 persevERA BC study (LBA1006), and an anbenitamab plus nab-docetaxel +/- carboplatin regimen in HER2-positive early breast cancer (LBA660).
The persevERA BC trial, which evaluates a novel HER2-targeted approach, attracted the most interest according to the poll results.
The poll highlights the community's focus on treatment sequencing, endocrine resistance and new antibody-drug conjugates that could shape future practice.
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026”
read at onclive ↗
comments(0)
5-min edit window · permanent after that